Small-molecule TrKB receptor agonists improve motor function and extend survival in a mouse model of huntington's disease

Human Molecular Genetics

Volumn 22, Issue 12, 2013, Pages 2462-2470

  Jiang, Mali ^a   Peng, Qi ^a   Liu, Xia ^b   Jin, Jing ^a   Hou, Zhipeng ^a   Zhang, Jiangyang ^a   Mori, Susumu ^a   Ross, Christopher A ^a   Ye, Keqiang ^b   Duan, Wenzhen ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' DIMETHYLAMINO 7,8 DIHYDROXYFLAVONE; 7,8 DIHYDROXYFLAVONE; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN DARPP 32; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN ATROPHY; BRAIN SIZE; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; HIPPOCAMPUS; HUNTINGTON CHOREA; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; NEOCORTEX; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; FEMALE; FLAVONES; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEURONS; RECEPTOR, TRKB; SIGNAL TRANSDUCTION; SURVIVAL;

MUS;

EID: 84878481329     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt098     Document Type: Article

References (54)

1. Vonsattel, J.P. and DiFiglia, M. (1998) Huntington disease. J. Neuropathol. Exp. Neurol., 57, 369-384.
2. Ross, C.A. and Tabrizi, S.J. (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol., 10, 83-98.
3. Krobitsch, S. and Kazantsev, A.G. (2011) Huntington's disease: from molecular basis to therapeutic advances. Int. J. Biochem. Cell Biol., 43, 20-24.
4. Gil-Mohapel, J.M. (2012) Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice. CNS Neurosci. Ther., 18, 77-86.
5. Rego, A.C. and de Almeida, L.P. (2005) Molecular targets and therapeutic strategies in Huntington's disease. Curr. Drug Target CNS Neurol. Disord., 4, 361-381.
6. Grimbergen, Y.A. and Roos, R.A. (2003) Therapeutic options for Huntington's disease. Curr. Opin. Investig. Drugs, 4, 51-54.
7. Bonelli, R.M., Wenning, G.K. and Kapfhammer, H.P. (2004) Huntington's disease: present treatments and future therapeutic modalities. Int. Clin. Psychopharmacol., 19, 51-62.
8. Zuccato, C., Liber, D., Ramos, C., Tarditi, A., Rigamonti, D., Tartari, M., Valenza, M. and Cattaneo, E. (2005) Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res., 52, 133-139.
9. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L., MacDonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R. et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493-498.
10. Zuccato, C. and Cattaneo, E. (2007) Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol., 81, 294-330.
11. Xie, Y., Hayden, M.R. and Xu, B. (2010) BDNF overexpression in the forebrain rescues Huntington' s disease phenotypes in YAC128 mice. J. Neurosci., 30, 14708-14718.
12. Giralt, A., Carreton, O., Lao-Peregrin, C., Martin, E.D. and Alberch, J. (2011) Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction. Mol. Neurodegener., 6, 71.
13. Duan, W., Guo, Z., Jiang, H., Ware, M., Li, X.J. and Mattson, M.P. (2003) Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc. Natl Acad. Sci. USA, 100, 2911-2916.
14. Duan, W., Peng, Q., Masuda, N., Ford, E., Tryggestad, E., Ladenheim, B., Zhao, M., Cadet, J.L., Wong, J. and Ross, C.A. (2008) Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol. Dis., 30, 312-322.
15. Peng, Q., Masuda, N., Jiang, M., Li, Q., Zhao, M., Ross, C.A. and Duan, W. (2008) The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp. Neurol., 210, 154-163.
16. Jiang, M., Wang, J., Fu, J., Du, L., Jeong, H., West, T., Xiang, L., Peng, Q., Hou, Z., Cai, H. et al. (2012) Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat. Med., 18, 153-158.
17. Chao, M.V. and Hempstead, B.L. (1995) p75 and Trk: a two-receptor system. Trends Neurosci., 18, 321-326.
18. Jang, S.W., Liu, X., Yepes, M., Shepherd, K.R., Miller, G.W., Liu, Y., Wilson, W.D., Xiao, G., Blanchi, B., Sun, Y.E. et al. (2010) A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc. Natl Acad. Sci. USA, 107, 2687-2692.
19. Liu, X., Chan, C.B., Jang, S.W., Pradoldej, S., Huang, J., He, K., Phun, L.H., France, S., Xiao, G., Jia, Y. et al. (2010) A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect. J. Med. Chem., 53, 8274-8286.
20. Mantilla, C.B. and Ermilov, L.G. (2012) The novel TrkB receptor agonist 7,8-dihydroxyflavone enhances neuromuscular transmission. Muscle Nerve, 45, 274-276.
21. Johnson, R.A., Lam, M., Punzo, A.M., Li, H., Lin, B.R., Ye, K., Mitchell, G.S. and Chang, Q. (2012) 7,8-dihydroxyflavone exhibits therapeutic efficacy in a mouse model of Rett syndrome. J. Appl. Physiol., 112, 704-710.
22. Devi, L. and Ohno, M. (2012) 7,8-Dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease. Neuropsychopharmacology, 37, 434-444.
23. Chen, J., Chua, K.W., Chua, C.C., Yu, H., Pei, A., Chua, B.H., Hamdy, R.C., Xu, X. and Liu, C.F. (2011) Antioxidant activity of 7,8-dihydroxyflavone provides neuroprotection against glutamate-induced toxicity. Neurosci. Lett., 499, 181-185.
24. Andero, R., Daviu, N., Escorihuela, R.M., Nadal, R. and Armario, A. (2012) 7,8-dihydroxyflavone, a TrkB receptor agonist, blocks long-term spatial memory impairment caused by immobilization stress in rats. Hippocampus, 22, 399-408.
25. Andero, R., Heldt, S.A., Ye, K., Liu, X., Armario, A. and Ressler, K.J. (2011) Effect of 7,8-dihydroxyflavone, a small-molecule TrkB agonist, on emotional learning. Am. J. Psychiatry, 168, 163-172.
26. Zhang, J., Peng, Q., Li, Q., Jahanshad, N., Hou, Z., Jiang, M., Masuda, N., Langbehn, D.R., Miller, M.I., Mori, S. et al. (2010) Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images. Neuroimage, 49, 2340-2351.
27. Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D. and Richardson, E.P. Jr. (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 44, 559-577.
28. de la Monte, S.M., Vonsattel, J.P. and Richardson, E.P. Jr. (1988) Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol., 47, 516-525.
29. Phillips, W., Morton, A.J. and Barker, R.A. (2006) Limbic neurogenesis/ plasticity in the R6/2 mouse model of Huntington's disease. Neuroreport, 17, 1623-1627.
30. Phillips, W., Morton, A.J. and Barker, R.A. (2005) Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment. J. Neurosci., 25, 11564-11576.
31. Grote, H.E., Bull, N.D., Howard, M.L., van Dellen, A., Blakemore, C., Bartlett, P.F. and Hannan, A.J. (2005) Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur. J. Neurosci., 22, 2081-2088.
32. Gil, J.M., Mohapel, P., Araujo, I.M., Popovic, N., Li, J.Y., Brundin, P. and Petersen, A. (2005) Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice. Neurobiol. Dis., 20, 744-751.
33. Tattersfield, A.S., Croon, R.J., Liu, Y.W., Kells, A.P., Faull, R.L. and Connor, B. (2004) Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease. Neuroscience, 127, 319-332.
34. Lazic, S.E., Grote, H., Armstrong, R.J., Blakemore, C., Hannan, A.J., van Dellen, A. and Barker, R.A. (2004) Decreased hippocampal cell proliferation in R6/1 Huntington's mice. Neuroreport, 15, 811-813.
35. Curtis, M.A., Penney, E.B., Pearson, A.G., van Roon-Mom, W.M., Butterworth, N.J., Dragunow, M., Connor, B. and Faull, R.L. (2003) Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc. Natl Acad. Sci. USA, 100, 9023-9027.
36. Zuccato, C., Marullo, M., Conforti, P., MacDonald, M.E., Tartari, M. and Cattaneo, E. (2008) Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol., 18, 225-238.
37. Gines, S., Bosch, M., Marco, S., Gavalda, N., Diaz-Hernandez, M., Lucas, J.J., Canals, J.M. and Alberch, J. (2006) Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur. J. Neurosci., 23, 649-658.
38. Greengard, P., Allen, P.B. and Nairn, A.C. (1999) Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron, 23, 435-447.
39. Fienberg, A.A., Hiroi, N., Mermelstein, P.G., Song, W., Snyder, G.L., Nishi, A., Cheramy, A., O'Callaghan, J.P., Miller, D.B., Cole, D.G. et al. (1998) DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science, 281, 838-842.
40. van Dellen, A., Welch, J., Dixon, R.M., Cordery, P., York, D., Styles, P., Blakemore, C. and Hannan, A.J. (2000) N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport, 11, 3751-3757.
41. Hickey, M.A., Kosmalska, A., Enayati, J., Cohen, R., Zeitlin, S., Levine, M.S. and Chesselet, M.F. (2008) Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience, 157, 280-295.
42. Ivkovic, S., Polonskaia, O., Farinas, I. and Ehrlich, M.E. (1997) Brain-derived neurotrophic factor regulates maturation of the DARPP-32 phenotype in striatal medium spiny neurons: studies in vivo and in vitro. Neuroscience, 79, 509-516.
43. Ivkovic, S. and Ehrlich, M.E. (1999) Expression of the striatal DARPP-32/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. J. Neurosci., 19, 5409-5419.
44. Stroppolo, A., Guinea, B., Tian, C., Sommer, J. and Ehrlich, M.E. (2001) Role of phosphatidylinositide 3-kinase in brain-derived neurotrophic factor-induced DARPP-32 expression in medium size spiny neurons in vitro. J. Neurochem., 79, 1027-1032.
45. Li, Y., Yui, D., Luikart, B.W., McKay, R.M., Rubenstein, J.L. and Parada, L.F. (2012) Conditional ablation of brain-derived neurotrophic factor-TrkB signaling impairs striatal neuron development. Proc. Natl Acad. Sci. USA, 109, 15491-15496.
46. Simpson, J.M., Gil-Mohapel, J., Pouladi, M.A., Ghilan, M., Xie, Y., Hayden, M.R. and Christie, B.R. (2011) Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. Neurobiol. Dis., 41, 249-260.
47. Kandasamy, M., Couillard-Despres, S., Raber, K.A., Stephan, M., Lehner, B., Winner, B., Kohl, Z., Rivera, F.J., Nguyen, H.P., Riess, O. et al. (2010) Stem cell quiescence in the hippocampal neurogenic niche is associated with elevated transforming growth factor-beta signaling in an animal model of Huntington disease. J. Neuropathol. Exp. Neurol., 69, 717-728.
48. Gil-Mohapel, J., Simpson, J.M., Ghilan, M. and Christie, B.R. (2011) Neurogenesis in Huntington's disease: can studying adult neurogenesis lead to the development of new therapeutic strategies? Brain Res., 1406, 84-105.
49. Li, Y., Luikart, B.W., Birnbaum, S., Chen, J., Kwon, C.H., Kernie, S.G., Bassel-Duby, R. and Parada, L.F. (2008) TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron, 59, 399-412.
50. Bergami, M., Berninger, B. and Canossa, M. (2009) Conditional deletion of TrkB alters adult hippocampal neurogenesis and anxiety-related behavior. Commun. Integr. Biol., 2, 14-16.
51. Liu, X., Chan, C.B., Qi, Q., Xiao, G., Luo, H.R., He, X. and Ye, K. (2012) Optimization of a small tropomyosin-related kinase B (TrkB) agonist 7,8-dihydroxyflavone active in mouse models of depression. J. Med. Chem., 55, 8524-8537.
52. Massa, S.M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J.N., Nehama, D., Rajadas, J. and Longo, F.M. (2010) Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J. Clin. Invest., 120, 1774-1785.
53. Schmid, D.A., Yang, T., Ogier, M., Adams, I., Mirakhur, Y., Wang, Q., Massa, S.M., Longo, F.M. and Katz, D.M. (2012) A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome. J. Neurosci., 32, 1803-1810.
54. Cheng, Y., Peng, Q., Hou, Z., Aggarwal, M., Zhang, J., Mori, S., Ross, C.A. and Duan, W. (2011) Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model. Neuroimage, 56, 1027-1034.